Application of a 3D Bioprinted Hepatocellular Carcinoma Cell Model in Antitumor Drug Research

Abstract

The existing in vitro models for antitumor drug screening have great limitations. Many compounds that inhibit 2D cultured cells do not exhibit the same pharmacological effects in vivo, thereby wasting human and material resources as well as time during drug development. Therefore, developing new models is critical. The 3D bioprinting technology has greater advantages in constructing human tissue compared with sandwich culture and organoid construction. Here, we used 3D bioprinting technology to construct a 3D model with HepG2 cells (3DP-HepG2). The biological activities of the model were evaluated by immunofluorescence, real-time quantitative PCR, and transcriptome sequencing. Compared with the traditional 2D cultured tumor cells (2D-HepG2), 3DP-HepG2 showed significantly improved expression of tumorrelated genes, including ALB, AFP, CD133, IL-8, EpCAM, CD24, and β-TGF genes. Transcriptome sequencing analysis revealed large differences in gene expression between 3DP-HepG2 and 2D-HepG2, especially genes related to hepatocyte function and tumor. We also compared the effects of antitumor drugs in 3DP-HepG2 and 2D-HepG2, and found that the large differences in drug resistance genes between the models may cause differences in the drugs' pharmacodynamics.

Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement

“…In vitro hepatocyte culture methods that mimic the in vivo-like microenvironment provide a potential platform for evaluating drug toxicity and screening of drugs which, in turn, improve the success rate of drug discovery in clinical trials. In recent years, the 3D bioprinting method have been employed to develop highcontent, physiologically relevant in vitro 3D liver models that reproduce the structures and functions of their native counterpart, for drug screening with accuracy [141][142][143][144][145][146][147][148].…”

3D Bioprinted cancer models: Revolutionizing personalized cancer therapy

“…An interesting study that used rapid light-based 3D bioprinting process, a liver decellularized ECM-based construct for HCC progression in a cirrhotic mechanical environment showed a higher expression of invasion associated markers in the HepG2 cells of bioprinted model [211] . In a study by Sun et al., a 3D bioprinted model with HepG2 cells was developed and compared with 2D cultured tumor cells [212] . Results showed a remarkable improvement in the expression of tumor-related genes including ALB, AFP, CD133, IL-8, EpCAM, CD24, and TGF-β genes in 3D bioprinted model.…”

Tackling Ischemic Reperfusion Injury With the Aid of Stem Cells and Tissue Engineering

“…Numerous research groups have been working to establish bioprinted platforms, especially in regenerative medicine and cancer research, to create clinically accurate ex vivo tissues and tumor models of different tissues. Their efforts have produced studies related to neovascularization, hypoxia, as well as oxygenreleasing scaffolds (Farina et al, 2017;Ong et al, 2018;Erdem et al, 2020;Sun et al, 2020), that support the idea that bioprinting could improve IRI models tissue-mimicry, especially to minimize preclinical trials.…”